RECRUITING

Bioresorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers

Conditions

Diabetic Foot Ulcer Ulcer Foot Diabetic Foot DFU Ulcer

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is a prospective, multi-center, randomized controlled trial designed to collect patient outcome data on 2 commercially available SOC treatments for Diabetic Foot Wounds.

Official Title

A Randomized Controlled Clinical Trial Evaluating The Efficacy Of A Borate-Based Bioactive Glass Advanced Wound Matrix And Standard Of Care Versus Standard Of Care Alone

Quick Facts

Study Start:2022-08-29

Study Completion:2024-12-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06403605

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Subjects must be at least 18 years of age or older. 2. Subjects must have a diagnosis of type 1 or 2 Diabetes mellitus. 3. At randomization subjects must have a target diabetic foot ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 20.0 cm2 measured post debridement with a photographic planimetry app. 4. The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care prior to the initial screening visit. 5. The target ulcer must be located on the foot with at least 50% of the ulcer below the malleolus. 6. The target ulcer must be full thickness on the foot or ankle that does not probe to bone. 7. Adequate circulation to the affected foot as documented by any of the following methods performed within 3 months of the first screening visit: 1. TCOM ≥30 mmHg 2. ABI between 0.7 and 1.3 3. PVR: Biphasic 4. TBI ˃0.6 5. As an alternative arterial Doppler ultrasound can be performed evaluating for biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle 8. If the subject has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer. 9. Target ulcers located on the plantar aspect of the foot must be offloaded for at least 14 days prior to randomization. 10. The subject must consent to using the prescribed off-loading method for the duration of the study. 11. The subject must agree to attend the weekly study visits required by the protocol. 12. The subject must be willing and able to participate in the informed consent process.	1. A subject known to have a life expectancy of \< 6 months is excluded. 2. If the target ulcer is infected or if there is cellulitis in the surrounding skin, the subject is excluded. 3. Presence of osteomyelitis or exposed bone, probes to bone or joint capsule on investigator's exam or radiographic evidence. 4. A potential subject cannot have an infection in the target ulcer or in a remote location that requires systemic antibiotic therapy. 5. A subject receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of Prednisone per day or equivalent) or cytotoxic chemotherapy is excluded. 6. The topical application of steroids to the ulcer surface within one month of initial screening is not permitted. 7. A subject with a previous partial amputation on the affected foot is excluded if the resulting deformity impedes proper offloading of the target ulcer. 8. If a subject has a glycated hemoglobin (HbA1c) greater than or equal to 12% taken at or within 3 months of the initial screening visit he/she is excluded. 9. If a subject has a serum creatinine ≥ 3.0mg/dL within 6 months of randomization he/she is excluded. 10. The subject is excluded if the surface area measurement of the target ulcer has reduced in size by more than 30% in the 2 weeks prior to the initial screening during the 2-week screening phase: the 2 weeks from the initial screening visit (SV1) to the TV1/randomization visit during which time the subject received SOC. 11. A subject with an acute Charcot foot, or an inactive Charcot foot, that impedes proper offloading of the target ulcer is excluded. 12. Women who are pregnant or considering becoming pregnant within the next 6 months are excluded. 13. A potential subject with end stage renal disease requiring dialysis is excluded. 14. A subject who participated in a clinical trial involving treatment with an investigational product within the previous 30 days is excluded. 15. A subject who, in the opinion of the Investigator, has a medical or psychological condition that may interfere with study assessments is excluded. 16. A subject treated with hyperbaric oxygen therapy or a Cellular and/or Tissue Product (CTP) in the 30 days prior to the initial screening visit is excluded.

Inclusion Criteria

Exclusion Criteria

1. Subjects must be at least 18 years of age or older.
2. Subjects must have a diagnosis of type 1 or 2 Diabetes mellitus.
3. At randomization subjects must have a target diabetic foot ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 20.0 cm2 measured post debridement with a photographic planimetry app.
4. The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care prior to the initial screening visit.
5. The target ulcer must be located on the foot with at least 50% of the ulcer below the malleolus.
6. The target ulcer must be full thickness on the foot or ankle that does not probe to bone.
7. Adequate circulation to the affected foot as documented by any of the following methods performed within 3 months of the first screening visit:
1. TCOM ≥30 mmHg
2. ABI between 0.7 and 1.3
3. PVR: Biphasic
4. TBI ˃0.6
5. As an alternative arterial Doppler ultrasound can be performed evaluating for biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle
8. If the subject has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer.
9. Target ulcers located on the plantar aspect of the foot must be offloaded for at least 14 days prior to randomization.
10. The subject must consent to using the prescribed off-loading method for the duration of the study.
11. The subject must agree to attend the weekly study visits required by the protocol.
12. The subject must be willing and able to participate in the informed consent process.

1. A subject known to have a life expectancy of \< 6 months is excluded.
2. If the target ulcer is infected or if there is cellulitis in the surrounding skin, the subject is excluded.
3. Presence of osteomyelitis or exposed bone, probes to bone or joint capsule on investigator's exam or radiographic evidence.
4. A potential subject cannot have an infection in the target ulcer or in a remote location that requires systemic antibiotic therapy.
5. A subject receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of Prednisone per day or equivalent) or cytotoxic chemotherapy is excluded.
6. The topical application of steroids to the ulcer surface within one month of initial screening is not permitted.
7. A subject with a previous partial amputation on the affected foot is excluded if the resulting deformity impedes proper offloading of the target ulcer.
8. If a subject has a glycated hemoglobin (HbA1c) greater than or equal to 12% taken at or within 3 months of the initial screening visit he/she is excluded.
9. If a subject has a serum creatinine ≥ 3.0mg/dL within 6 months of randomization he/she is excluded.
10. The subject is excluded if the surface area measurement of the target ulcer has reduced in size by more than 30% in the 2 weeks prior to the initial screening during the 2-week screening phase: the 2 weeks from the initial screening visit (SV1) to the TV1/randomization visit during which time the subject received SOC.
11. A subject with an acute Charcot foot, or an inactive Charcot foot, that impedes proper offloading of the target ulcer is excluded.
12. Women who are pregnant or considering becoming pregnant within the next 6 months are excluded.
13. A potential subject with end stage renal disease requiring dialysis is excluded.
14. A subject who participated in a clinical trial involving treatment with an investigational product within the previous 30 days is excluded.
15. A subject who, in the opinion of the Investigator, has a medical or psychological condition that may interfere with study assessments is excluded.
16. A subject treated with hyperbaric oxygen therapy or a Cellular and/or Tissue Product (CTP) in the 30 days prior to the initial screening visit is excluded.

Contacts and Locations

Study Contact

Donald W Buck II, MD

CONTACT

510-490-5998

dbuck@etswoundcare.com

Zachary Davis

CONTACT

573-201-4023

zachary.davis@heraeus.com

Principal Investigator

David Armstrong, DPM, MD, PhD

STUDY_CHAIR

USC/Salsa

Charles M Zelen, DPM

PRINCIPAL_INVESTIGATOR

Professional Education and Research Institute

Robert Galiano, MD

STUDY_CHAIR

Professor of Surgery, Plastic Surgery, Northwestern University School of Medicine, Chicago, IL

Study Locations (Sites)

LA Foot and Ankle

Los Angeles, California, 90010

United States

Casa Colina

Pomona, California, 91769

United States

Center for Clincal Research

San Francisco, California, 94115

United States

Southernmost Foot and Ankle Specialists

Homestead, Florida, 33030

United States

Doctor's Research Network

South Miami, Florida, 33143

United States

Gateway Clinical Trials

O'Fallon, Illinois, 62269

United States

Foot and Ankle Center of Illinois

Springfield, Illinois, 62704

United States

Mercy Medical Center

Cedar Rapids, Iowa, 52403

United States

Foot and Ankle Specialists of the Mid Atlantic

Frederick, Maryland, 21703

United States

Wound Care Experts

Las Vegas, Nevada, 89148

United States

Lower Extremity Institute for Research and Therapy

Youngstown, Ohio, 44512

United States

Wound Centrics

Corpus Christi, Texas, 78404

United States

PULSE: Amputation Prevention Center, LLC

El Paso, Texas, 79902

United States

Foot and Ankle Specialists of the Mid Atlantic

Salem, Virginia, 24153

United States

United Wound Healing P.S

Auburn, Washington, 98092

United States

Collaborators and Investigators

Sponsor: ETS Wound Care, LLC

David Armstrong, DPM, MD, PhD, STUDY_CHAIR, USC/Salsa
Charles M Zelen, DPM, PRINCIPAL_INVESTIGATOR, Professional Education and Research Institute
Robert Galiano, MD, STUDY_CHAIR, Professor of Surgery, Plastic Surgery, Northwestern University School of Medicine, Chicago, IL

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-08-29

Study Completion Date2024-12-31

Study Record Updates

Study Start Date2022-08-29

Study Completion Date2024-12-31

Terms related to this study

Keywords Provided by Researchers

DFU
Ulcer

Additional Relevant MeSH Terms

Diabetic Foot Ulcer
Ulcer Foot
Diabetic Foot